Novartis under scrutiny in Japan

Share this article:
Novartis announces good heart drug results
Novartis announces good heart drug results

Allegations of misconduct are driving doctors away from Novartis' heart medicine Diovan and drawing attention from government authorities in Japan. Pharmalot reported that government reps will raid the drug maker's officers, following a health ministry report that the company is responsible for falsified research that exaggerated the drug's benefits, a violation of the country's Pharmaceutical Affairs Act. Investigations into questionable research spanned the summer and, Pharmalot noted, elicited admissions from two employees in May that they had been involved in clinical trials, an intersection of drug company employees and researchers that was later confirmed by a third party. The scandal has resulted in retracted papers, lost hospital prescriptions and several university investigations.

Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.